Efficacy and safety of a cisplatin and paclitaxel induction regimen followed by chemoradiotherapy for patients with locally advanced head and neck squamous cell carcinoma
| Autor: | Felipe Coelho de Aguiar Silva, Luciano de Souza Viana, Carlos Roberto dos Santos, Marcos Duarte de Mattos, André Lopes Carvalho, Renato de Castro Capuzzo, Domingos Boldrini Junior, Alexandre A. Jácome, Alexandre Arthur Jacinto, Augusto Elias Mamere, Danielle Calheiros Campelo Maia |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
0301 basic medicine
Cisplatin Oncology medicine.medical_specialty business.industry medicine.medical_treatment Head and neck cancer Induction chemotherapy medicine.disease Head and neck squamous-cell carcinoma Radiation therapy 03 medical and health sciences Regimen 030104 developmental biology 0302 clinical medicine Otorhinolaryngology Tolerability 030220 oncology & carcinogenesis Internal medicine medicine business Chemoradiotherapy medicine.drug |
| Zdroj: | Head & Neck. 38:E970-E980 |
| ISSN: | 1043-3074 |
| Popis: | Background The purpose of this phase II trial was to evaluate the tolerability, safety, and efficacy of a non–5-fluorouracil (5-FU)-based induction chemotherapy followed by chemoradiotherapy (CRT) for patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Methods Sixty patients with stage III to IV HNSCC were treated with induction paclitaxel and cisplatin (TP; paclitaxel 175 mg/m2 and cisplatin 80 mg/m2, 3 cycles) followed by CRT (cisplatin 100 mg/m2; D1, 22, and 43 of radiotherapy). Results Fifty-six patients (93.3%) completed 3 cycles of induction TP (no treatment-related deaths), 52 (86.7%) completed definitive CRT per protocol (adverse event [AE] grade ≥2 in 53.3%). The overall response rate after induction TP was 82.5% for patients with resectable disease and 55.5% for unresectable disease (p = .023), and complete response (CR) rate after CRT was 70.0% for patients with resectable disease and 30.0% for unresectable disease (p = .005). Conclusion Induction TP followed by cisplatin based-CRT was well-tolerated, safe, and had high overall response rate in selected patients with locally advanced HNSCC. © 2015 Wiley Periodicals, Inc. Head Neck, 2015 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text